For research use only
| Cat No. | ABL-TC0611 |
| Product Type | Human Tongue Cancer Cell Lines |
| Species | Human |
| Growth Conditions | 37 ℃, 5% CO2 |
| Source Organ | Tongue |
Human SAS tongue carcinoma cells model oral squamous and head-neck cancers, showing tumorigenicity and epithelial growth traits.
SAS is a human oral squamous cell carcinoma (OSCC) cell line derived from a poorly differentiated tongue tumor in a Japanese male patient and is widely referenced in research as a representative SAS cell line within broader oral cancer cell lines used for studying epithelial malignancies. These adherent cells exhibit cobblestone-like epithelial morphology and can be stably passaged in vitro. SAS cells express epithelial and squamous markers such as cytokeratins and E-cadherin, and harbor mutations in tumor suppressor genes like TP53, commonly implicated in OSCC pathogenesis. They display a high proliferation rate, strong invasive capacity, and responsiveness to signaling pathways involved in epithelial–mesenchymal transition (EMT). Due to their tumorigenicity and consistent behavior in culture, SAS cells are widely used to investigate mechanisms of oral cancer progression, metastasis, and resistance to therapy.
| Species | Human |
| Cat.No | ABL-TC0611 |
| Product Category | Tumor Cell Lines |
| Size/Quantity | 1 vial |
| Shipping Info | Dry Ice |
| Growth Conditions | 37 ℃, 5% CO2 |
| Source Organ | Tongue |
| Biosafety Level | 1 |
| Storage | Liquid Nitrogen |
| Product Type | Human Tongue Cancer Cell Lines |
SAS cells enable research in tongue cancer biology, including tumor growth, invasion, metastasis, and therapeutic responses. They support efficacy assessments of platinum-based agents, taxanes, and valproic acid using xenograft models, preclinical drug screening, and in vivo studies of tumor behavior and microenvironment interactions. These cells facilitate CDX model development for tumor intervention studies, mechanistic exploration of cancer progression, translational research bridging basic and clinical science, and immunotherapy investigations.
When you publish your research, please cite our product as “AcceGen Biotech Cat.# XXX-0000”. In return, we’ll give you a $200 coupon. Simply click here and submit your paper’s PubMed ID (PMID).
